|
Neurodegenerative Diseases: World Drug Market 2011-2026
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
Our report gives you the following advantages:You can have our report today Our new study can benefit everybody interested in the neurodegenerative disease treatment market. You can see where the industry and market are heading, assessing the opportunities, requirements and challenges there. You can find answers and trends - we aim to save you time and aid your decisions. Order our report now, making sure you don't miss out. Please let us help today. Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6 182 seiten | |||||||||||
| Inhalt der Studie: |
Would you like to know how the industry and market for neurodegenerative drug treatments will develop? There will be trends to watch from 2010 onwards, especially areas of revenue growth. You can have.....
Would you like to know how the industry and market for neurodegenerative drug treatments will develop? There will be trends to watch from 2010 onwards, especially areas of revenue growth. You can have our new report now, staying ahead, saving time and aiding your decisions. The number of patients may quadruple worldwide by 2050. Yet, there remain significant unmet needs in all sectors of the neurodegenerative treatments market. You can assess those commercial opportunities now, with us providing forecasts for the following drug markets from 2010 to 2026: • Multiple sclerosis • Alzheimer's disease • Parkinson's disease • Neuropathies • Huntington's disease • Amyotrophic lateral sclerosis. Our new report analyses and discusses strengths, weaknesses and revenue trends of the sector from 2009 to 2026. All sectors of the market have been expanding, but which will fare best from 2010 onwards? How will those submarkets, and the overall market sector, cope with patent expiries this decade? How will leading national markets perform from 2010 to 2026? What opportunities are there for resolving unmet therapeutic needs? We show you where the neurodegenerative drug treatment sector is heading. Our report shows you its technological and commercial potential, revealing opportunities, challenges and requirements for success there. New drugs with improved safety and efficacy can gain significant market shares from 2010 onwards. There remain high revenues to be made in this sector from 2010 to 2026, as we show and explain. New treatment types - such as oral agents for MS - could re-shape the market from this decade onwards. There will be commercial growth, with important trends to watch. We show how you could make gains there. Our report makes it quick and practical for you to assess the potential of the industry and market now. Analysis and expert views to aid your work - so you won't be left behind Our new report provides you with revenue forecasts, market share analyses, R&D pipeline developments and expert opinion. That way, you can assess prospects, opportunities and threats in the sector. It is that combination of data that sets us apart. We include 98 tables and figures and two expert interviews (shown in the accompanying lists). You can stay ahead by ordering our report today, benefiting your analyses and commercial ideas. [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 Overview of Findings 1.2 Chapter Breakdown 1.3 Research and Analysis Methods 2. Neurodegenerative Diseases: An Introduction 2.1 What Are Neurodegenerative Diseases? 2.2 Multiple Sclerosis (MS) 2.2.1 Treatment Options 2.3 Alzheimer's Disease 2.3.1 Treatment Options 2.4 Parkinson's Disease 2.4.1 Treatment Options 2.5 Neuropathies 2.5.1 Neuropathic Pain 2.5.2 Treatment Options 2.5.2.1 Pharmacological Treatments 2.6 Huntington's Disease 2.6.1 Treatment Options 2.7 Amyotrophic Lateral Sclerosis (ALS) 2.7.1 Treatment Options 3. World Neurodegenerative Diseases Drug Market 2009-2026 3.1 Analysis of the Market in 2009 3.1.1 A Market Dominated by Blockbusters 3.2 Neurodegenerative Diseases: Market Forecast 2010-2026 3.2.1 Market Forecast 2010-2016 3.2.2 Blockbuster Patent Expiries 3.2.3 Symptom Treatment over Disease Modification 3.2.4 Market Forecast 2016-2026 3.2.4.1 Rapid Growth in Smaller Markets 4. Multiple Sclerosis (MS) Market 4.1 Treatment Available for MS 4.1.1 Treatment for Symptoms 4.1.2 Disease-Modifying Medicines 4.2 MS Market in 2009 4.3 MS Market Forecast 2010-2026 4.3.1 Market Forecast 2010-2016 4.3.2 Market Forecast 2016-2026 4.3.3 Oral Treatments 4.3.4 An Approval Pathway for Biosimilars 4.4 Copaxone 4.4.1 Copaxone Sales Forecast 2010-2026 4.4.2 Patent Expiry and Competition 4.5 Avonex 4.5.1 Avonex Sales Forecast 2010-2016 4.5.2 Avonex Long-Term Forecast 2016-2026 4.6 Rebif 4.6.1 Rebif Sales Forecast 2010-2016 4.6.2 Rebif Will Be Challenged Beyond 2016 4.7 Betaferon 4.7.1 Betaferon and Generic Competition 4.8 Tysabri 4.9 MS Pipeline Analysis 4.9.1 Oral Treatments 4.9.2 Monoclonal Antibodies 4.9.3 Vaccines 5. Alzheimer's Disease Market 5.1 There Are Only Five Drugs Approved for Treating Alzheimer's 5.2 Analysis of the Market in 2009 5.3 Alzheimer's Market Forecast 2010-2026 5.3.1 Market Forecast 2010-2016 5.3.2 Market Forecast 2016-2026 5.4 Aricept 5.4.1 Aricept Sales Forecast 2010-2026 5.5 Namenda 5.5.1 Namenda Sales Forecast 2010-2026 5.6 Exelon 5.6.1 Exelon Sales Forecast 2010-2026 5.7 Alzheimer's R&D Pipeline: Analysis 5.7.1 Gamma Secretase Inhibitors 5.7.1.1 Tau Inhibitors 5.7.2 Immunotherapy 5.7.2.1 Monoclonal Antibodies 5.7.2.2 IVIg 5.7.3 Amyloid-? Detection 6. Parkinson's Disease Market 6.1 Parkinson's Market in 2009 6.2 Parkinson's Market Forecast 2010-2026 6.3 Sifrol 6.3.1 Sifrol Sales Forecast 2010-2026 6.4 Stalevo & Comtess 6.4.1 Stalevo for Early Stage Parkinson's 6.4.2 Stalevo & Comtess Sales Forecast 2010-2026 6.5 Requip 6.5.1 Requip Sales Forecast 2010-2026 6.6 Azilect 6.6.1 Azilect Delays Disease Progression 6.6.2 Azilect Sales Forecast 2010-2026 6.7 Future Therapy for Parkinson's 6.7.1 Developments for Levodopa 6.7.2 KW-6002 6.7.3 Safinamide 6.7.4 Gene Therapy Could Soon Be a Treatment Option 6.7.4.1 Ceregene 6.7.4.2 Neurologix 6.7.5 Long-Term Treatment Options 7. Neuropathies Market 7.1 Treatment Options 7.1.1 Anticonvulsants 7.1.2 Analgesics 7.1.2.1 Local Anaesthetics 7.1.3 Antidepressants 7.1.4 Aldose Reductase Inhibitors 7.1.4.1 Kinedak 7.2 Neuropathy Market in 2009 7.3 Neuropathy Market Forecast 2010-2026 7.3.1 Market Forecast 2010-2016 7.3.2 Market Forecast 2016-2026 7.3.3 Neurontin: The Forerunner of Lyrica 7.3.4 Qutenza is a Recently-Approved Neuropathy Treatment 7.4 Lyrica Sales Forecast 2010-2026 7.4.1 Lyrica Patents Expire in 2013 and 2018 7.5 Future Treatment of Neuropathies 7.5.1 AS-3201 7.5.2 KRN5500 7.5.3 Epicept NP-1 7.5.4 Secondary Indication Drugs 7.5.5 J&J and Monoclonal Antibodies 8. Huntington's Disease Market 8.1 Huntington's Market in 2009 8.2 Huntington's Market Forecast 2010-2026 8.3 Xenazine 8.3.1 Xenazine Sales Analysis, 2009 8.3.2 Xenazine Sales Forecast 2010-2026 8.4 R&D Pipeline Analysis 8.4.1 Huntexil 8.4.2 Dimebon 8.4.3 Antioxidant Therapy 8.4.4 RNAi as a Potential Treatment 9. Amyotrophic Lateral Sclerosis (ALS) Market 9.1 ALS Market in 2009 9.2 ALS Market Forecast 2010-2026 9.2.1 ALS Market Forecast: Best Case Scenario 9.2.2 ALS Market Forecast: Worst Case Scenario 9.3 Rilutek 9.3.1 Rilutek Sales Forecast 2010-2026 9.4 R&D Pipeline Analysis 9.4.1 Olesoxime 9.4.2 Mecobalamin 9.4.3 Radicut 9.4.4 Dexpramipexole 10. Leading National Market Forecasts 2010-2026 10.1 US Market: Forecast 2010-2026 10.2 Leading European Markets: Forecasts 2010-2026 10.3 Japanese Market: Forecast 2010-2026 10.4 Leading Emerging Markets: Forecasts 2010-2026 10.4.1 China 10.4.2 India 11. Issues Affecting the Neurodegenerative Diseases Market 2010-2026 11.1 SWOT Analysis of the Neurodegenerative Diseases Market 2010-2026 11.2 Strengths 11.2.1 Neurodegenerative Diseases Are High Profile 11.2.2 Chronic Diseases: Long-Term Repeat Sales 11.3 Weaknesses 11.3.1 Side Effects Associated with Treatment 11.3.2 The High Costs of Treatment 11.3.3 High Product Competition 11.4 Opportunities 11.4.1 Significant Unmet Needs Still Exist in the Market 11.4.2 Aging Populations Will Lead to Increased Disease Prevalence 11.4.3 Orphan Status and Fast Track Reviews for New Drugs 11.5 Threats 11.5.1 Patent Expiries Will Lead to Generic Competition 11.5.2 New Therapies Offer an Alternative to Drug Treatment 11.5.2.1 Neurostimulation 11.5.2.2 Stem Cell Therapy 11.5.2.3 Gene Therapy 12. Expert Opinions 12.1 Interview with Professor Lisa Ellerby 12.1.1 Future Treatment Possibilities 12.1.2 The Market Potential for a Huntington's Disease Cure 12.2 Interview with Professor Jürgen Götz 12.2.1 The Obstacles for Developing a Cure for Alzheimer's Disease 12.2.2 The Time Frame for Developing a Cure for Alzheimer's Disease 12.2.3 Potential Alzheimer's Disease Treatments 12.2.4 The Market Potential for a Cure for Alzheimer's Disease 13. Conclusions 13.1 Rising Prevalence Due to Aging Population to Drive Market Growth 13.2 All Markets Have Significant Unmet Needs 13.3 Pipelines for Some Diseases Are Stronger Than Others 13.4 Conclusions for Individual Market Sectors 13.4.1 Oral Treatments Will Alter the MS Market 13.4.2 Alzheimer's Symptom Management Therapies Will Remain Competitive 13.4.3 Patent Expiries to Hit the Parkinson's Market 13.4.4 Indication-Specific Drugs Will Expand the Neuropathies Market 13.4.5 Blockbuster Potential for Novel Huntington's Drugs 13.4.6 The ALS Market is Difficult to Predict [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1 Prevalence of Neurodegenerative Diseases, 2010 Table 2.2 Life Expectancy for Prion Diseases, 2010 Table 2.3 Common Causes of Neuropathies, 2010 Table 3.1 Neurodegenerative Diseases: Blockbuster Drugs, 2009 Table 3.2 World Neurodegenerative Diseases Market Forecast, 2009-2016 Table 3.3 Neurodegenerative Diseases Drivers and Restraints, 2010-2026 Table 3.4 Blockbuster Patent Expiries, 2009-2015 Table 3.5 World Neurodegenerative Diseases Market Forecast, 2016-2026 Table 4.1 Leading MS Drug Sales, 2009 Table 4.2 MS Drug Market Forecast, 2009-2016 Table 4.3 MS Drug Market Forecast, 2016-2026 Table 4.4 Selected Pipeline Treatments for MS in Phase II & III, 2010 Table 5.1 FDA Approved Alzheimer's Therapeutics, 2010 Table 5.2 Leading Alzheimer's Drug Sales, 2009 Table 5.3 Earliest Expected Approvals for Anti-Alzheimer's Treatments in Phase III, 2010 Table 5.4 Alzheimer's Drug Market Forecast, 2009-2016 Table 5.5 Alzheimer's Drug Market Forecast, 2016-2026 Table 5.6 Selected Pipeline Treatments for Alzheimer's in Phase II & III, 2010 Table 6.1 Leading Parkinson's Drug Sales, 2009 Table 6.2 Patent Expiries Affecting the Parkinson's Market, 2008-2013 Table 6.3 Parkinson's Drug Market Forecast, 2009-2016 Table 6.4 Parkinson's Drug Market Forecast, 2016-2026 Table 6.5 Stalevo & Comtess Sales, 2009 Table 6.6 Selected Pipeline Treatments for Parkinson's in Phase II & III, 2010 Table 7.1 Key Therapeutics Indicated for Neuropathies, 2010 Table 7.2 Leading Neuropathy Drug Sales, 2009 Table 7.3 Neuropathy Drug Market Forecast, 2009-2016 Table 7.4 Neuropathy Drug Market Forecast, 2016-2026 Table 7.5 The Rising Prevalence of Diabetes, 2010-2030 Table 7.6 Selected Pipeline Treatments for Neuropathies in Phase II & III, 2010 Table 8.1 Treatment Options for Huntington's, 2010 Table 8.2 Huntington's Drug Market Forecast, 2009-2016 Table 8.3 Huntington's Drug Market Forecast, 2016-2026 Table 8.4 Global Xenazine Sales, 2009 Table 8.5 Selected Pipeline Treatments for Huntington's in Phase II & III, 2010 Table 9.1 ALS Drug Market: Best Case Scenario Forecast, 2009-2016 Table 9.2 ALS Drug Market: Best Case Scenario Forecast, 2016-2026 Table 9.3 ALS Drug Market: Worst Case Scenario Forecast, 2009-2016 Table 9.4 ALS Drug Market: Worst Case Scenario Forecast, 2016-2026 Table 9.5 Selected Pipeline Treatments for ALS in Phase II & III, 2010 Table 10.1 Neurodegenerative Diseases Market: National Forecasts, 2009-2016 Table 10.2 Neurodegenerative Diseases Market: National Forecasts, 2016-2026 Table 11.1 SWOT Chart for the Neurodegenerative Diseases Market, 2010-2026 Table 11.2 Population Proportions (%) Aged Over 65, 2009-2050 Table 11.3 Progress of Alternative Therapies for Neurodegenerative Diseases, 2010 Table 13.1 World Neurodegenerative Disease Market: Forecast Summary, 2009-2026 Figure 2.1 The Five Stages of Parkinson's Disease Figure 3.1 World Neurodegenerative Diseases: Market Shares by Sector, 2009 Figure 3.2 Neurodegenerative Diseases: Blockbuster Drugs, 2009 Figure 3.3 World Neurodegenerative Diseases Market Forecast, 2009-2016 Figure 3.4 World Neurodegenerative Diseases: Market Shares by Sector, 2016 Figure 3.5 World Neurodegenerative Diseases Market Forecast, 2016-2026 Figure 3.6 World Neurodegenerative Diseases: Market Shares by Sector, 2026 Figure 4.1 Leading MS Drug Sales, 2009 Figure 4.2 MS Drug Market Forecast, 2009-2016 Figure 4.3 Leading MS Drug Market Shares, 2016 Figure 4.4 Leading MS Drug Market Shares, 2026 Figure 4.5 MS Drug Market Forecast, 2016-2026 Figure 4.6 Copaxone Sales Forecast, 2009-2026 Figure 4.7 Avonex Sales Forecast, 2009-2026 Figure 4.8 Rebif Sales Forecast, 2009-2026 Figure 4.9 Betaferon Sales Forecast, 2009-2026 Figure 5.1 Leading Alzheimer's Drug Sales, 2009 Figure 5.2 Alzheimer's Drug Market Forecast, 2009-2016 Figure 5.3 Leading Alzheimer's Drugs: Market Shares, 2009, 2016 & 2026 Figure 5.4 Leading Alzheimer's Drug Market Forecast, 2016-2026 Figure 5.5 Aricept Sales Forecast, 2009-2026 Figure 5.6 Namenda Sales Forecast, 2009-2026 Figure 5.7 Exelon Sales Forecast, 2009-2026 Figure 6.1 Leading Parkinson's Drug Sales, 2009 Figure 6.2 Parkinson's Drug Market Forecast, 2009-2016 Figure 6.3 Parkinson's Drug Market Forecast, 2016-2026 Figure 6.4 Leading Parkinson's Drugs: Market Shares, 2009, 2016 & 2026 Figure 6.5 Sifrol Sales Forecast, 2009-2026 Figure 6.6 Stalevo & Comtess Sales, 2009 Figure 6.7 Stalevo & Comtess Sales Forecast, 2009-2026 Figure 6.8 Requip Sales Forecast, 2009-2026 Figure 6.9 Azilect Sales Forecast, 2009-2026 Figure 7.1 Leading Neuropathy Drug Sales, 2009 Figure 7.2 Neuropathy Drug Market Forecast, 2009-2016 Figure 7.3 Neuropathy Drug Market Forecast, 2016-2026 Figure 7.4 The Rising Prevalence of Diabetes, 2010-2030 Figure 7.5 Lyrica Sales Forecast, 2009-2026 Figure 8.1 Huntington's Drug Market Forecast, 2009-2026 Figure 8.2 Global Xenazine Sales, 2009 Figure 8.3 Xenazine Sales Forecast, 2009-2026 Figure 9.1 ALS Drug Market: Best Case Scenario Forecast, 2009-2026 Figure 9.2 ALS Drug Market: Worst Case Scenario Forecast, 2009-2026 Figure 9.3 Comparison of ALS Drug Market Scenarios, 2009, 2016 & 2026 Figure 9.4 Rilutek Sales Forecast, 2009-2026 Figure 10.1 Neurodegenerative Diseases Market: National Shares, 2009 Figure 10.2 Neurodegenerative Diseases Market: National Shares, 2016 Figure 10.3 Neurodegenerative Diseases Market: National Shares, 2026 Figure 10.4 US Market Forecast, 2009-2026 Figure 10.5 European Market Forecasts, 2009-2026 Figure 10.6 Japanese Market Forecast, 2009-2026 Figure 10.7 Chinese and Indian Market Forecasts, 2009-2026 Figure 11.1 Proportion of Population Aged Over 65 by Region, 2009-2050 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
